$COLL News

Collegium Pharmaceutical, Inc. 2026 Q1 - Results - Earnings Call Presentation

Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript

Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36%

Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $805.000M-$825.000M vs $825.757M Est

Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate

Collegium Pharmaceutical Inc (NASDAQ:COLL) Priced for a Value Rebound

Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth - Slideshow

Collegium Pharmaceutical: Another M&A Episode Adds To An Intriguing Case

HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $60 Price Target

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript

Collegium To Acquire AZSTARYS For $650M In Cash With Potential For Additional Milestone Payments Up To $135M Depending On Future Commercial And Regulatory Milestones

Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference

A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure

Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results

Collegium to Present New Real-World Data at PainConnect 2026

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical, Inc. 2025 Q4 - Results - Earnings Call Presentation